Biocon's anti-CD6 mAb meets Phase III psoriasis endpoint

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said itolizumab met the primary endpoint of a significantly greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo in the Phase III TRE...